A Phase 2 interventional study of adriamycin and bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag International NV. Terminated at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-21.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 171st largest by enrollment of the 267 interventional ones that give a count, is one of 29 that started in 2006, is one of 137 in phase 2, and was the 61st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 29 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 78th largest by enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2006, is one of 32 in phase 2, and was the 18th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to test the safety and effectiveness of replacing vincristine with a drug called bortezomib (also known as "Velcade"or PS341) in the standard therapy vincristine, doxorubicin (not limited to, but formerly referred to under the tradename Adriamycin) and dexamethasone (VAD) in patients with multiple myeloma. Multiple Myeloma is the second most common cancer of the blood. Bortezomib is the first approved cancer treatment in a new class of medicines called proteasome inhibitors. It disrupts the cell cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells. The treatment will be used as second line treatment, which means either the disease has returned after a period of improvement (relapse) or the disease did not respond to the initial treatment (refractory). Patients will receive either bortezomib (PS341), doxorubicin (Adriamycin) and dexamethasone (PAD) or the VAD standard therapy.
Bortezomib, has been approved for use in patients with multiple myeloma, who have already received at least one prior treatment and whose disease is worsening on their last treatment and who have already undergone or are unsuitable for bone marrow transplantation. Bortezomib has significant activity in patients with relapsed multiple myeloma, its efficacy is increased with the addition of dexamethasone and it demonstrates synergy with doxorubicin. The VAD combination has been widely used in multiple myeloma and has demonstrated to be effective in relapsed patients. Based on previous trial results, it is hoped that bortezomib, in replacing vincristine in the VAD standard therapy, can improve the response to treatment of patients with multiple myeloma, with manageable side effects. This is an international, multicentre, randomised, open-label, parallel group study. About 212 patients will take part in the study. Patients will be treated with either bortezomib (PS-341), Adriamycin and Dexamethasone (PAD) or Vincristine, Adriamycin and Dexamethasone (VAD). There will be an initial 14 day screening period to evaluate if the patient is suitable for the study. After screening, eligible patients will be randomised to receive either PAD or VAD. Patients will receive therapy for up to 8 treatment cycles of 28 days each. After the treatment period, there will be a long-term follow-up period with monthly visits until disease progression or relapse. Thereafter follow-up will be continued by at least a phone call every other month. This long-term follow-up period will be performed for all patients until the last patient was treated and followed up for 1 year. Response to treatment will be assessed according to the European group for blood and marrow transplant criteria (EBMT). Disease burden will be monitored by measuring M-protein concentration in serum and in urine every 4 weeks until disease progression or relapse. Thereafter follow-up for survival will be continued every other month by at least a phone call. Safety will be assessed by monitoring of adverse events (AEs), vital signs, physical examination and clinical laboratory tests. Treatment with PAD or VAD will be for up to 8 cycles of 28 days each. Treatment beyond 6 cycles will be discussed on individual basis. Proposed dosages are: bortezomib 1.3 mg/m² intravenous (IV) bolus on Days 1, 4, 8, and 11; vincristine 0.4mg IV push on Days 1 to 4; doxorubicin 9mg/m² IV push on Days 1 to 4; dexamethasone in 1st cycle 40 mg daily on Days 1 to 4, 9 to 12 and 17 to 20, orally (or equivalent parenteral dose) and on subsequent cycles as 40 mg daily on Days 1 to 4 and 17 to 20 only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vincristine in combination with adriamycin and dexamethasone
Drug: adriamycin · Drug: dexamethasone · Drug: vincristine
bortezomib in combination with adriamycin and dexamethasone
Drug: adriamycin · Drug: bortezomib · Drug: dexamethasone
adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
vincristine: 0.4mg IV push on days 1 to 4
Best Confirmed Disease Response
The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator. The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease \[PD\], 1 to 3 weeks apart). The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD. CR was the best response and the poorest response was PD.
Time frame: every 28 days during treatment period for up to 6 to 8 cycles
Best Reported Disease Response
The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator. The ordering of the responses was: CR, PR, MR, NC and PD. CR was the best response and the poorest response was PD.
Time frame: every 28 days during treatment period for up to 6 to 8 cycles
Duration of Response (DOR)
DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = (\[Date of PD or date of censoring - Date of best response\]+1)/30.44.
Time frame: every 28 days during treatment period for up to 6 to 8 cycles
Subjects were recruited from 05 December 2006 to 04 July 2007 at 2 sites in Germany, 1 site in Hungary, 3 sites in Lithuania, 3 sites in Poland and 3 sites in Russia
| Milestone | VAD Treatment | PAD Treatment |
|---|---|---|
| Started | 17 | 13 |
| Treated | 16 | 13 |
| Completed | 6 | 7 |
| Not completed | 11 | 6 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Progressive disease | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Qualified for stem-cell transplantation | 3 | 0 |
| Withdrew: Refractory disease | 1 | 0 |
| Milestone | VAD Treatment | PAD Treatment |
|---|---|---|
| Started | 17 | 13 |
| Completed | 5 | 4 |
| Not completed | 12 | 9 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Other | 1 | 3 |
The primary efficacy analysis was based on the best response obtained during the treatment period according to the European Group for Blood and Marrow Transplantation (EBMT) criteria as assessed by the investigator. The best confirmed response was defined as 2 separate and consecutive evaluations of response, at least 6 weeks apart (for progressive disease \[PD\], 1 to 3 weeks apart). The ordering of the responses was: complete response (CR), partial response (PR), minimal response (MR), no change (NC) and PD. CR was the best response and the poorest response was PD.
| participants | VAD Treatment | PAD Treatment |
|---|---|---|
| CR | 0 | 1 |
| PR | 5 | 6 |
| Response Rate (CR + PR) | 5 | 7 |
| MR | 2 | 0 |
| Overall Response (CR + PR + MR) | 7 | 7 |
| NC | 3 | 1 |
| PD | 1 | 1 |
| Unknown/Unable to Assess | 4 | 4 |
The primary efficacy analysis was based on the best response obtained during the treatment period according to the EBMT criteria as assessed by the investigator. The ordering of the responses was: CR, PR, MR, NC and PD. CR was the best response and the poorest response was PD.
| participants | VAD Treatment | PAD Treatment |
|---|---|---|
| CR | 1 | 3 |
| PR | 6 | 4 |
| Response Rate (CR + PR) | 7 | 7 |
| MR | 2 | 3 |
| Overall Response (CR + PR + MR) | 9 | 10 |
| NC | 5 | 3 |
| PD | 0 | 0 |
| Unknown/Unable to Assess | 1 | 0 |
DOR was defined as the duration from the date of the best confirmed response for subjects who achieved CR or PR to the date of first documented evidence of PD (or relapse for subjects who experienced CR) over the duration of the study. DOR = (\[Date of PD or date of censoring - Date of best response\]+1)/30.44.
| months | VAD Treatment | PAD Treatment |
|---|---|---|
| patient 1 | 1.68 (1.68 to 6.18) | 2.83 (2.83 to 7.69) |
| patient 2 | 6.18 | 7.69 |
| patient 3 | 3.71 | 5.52 |
| patient 4 | 5.42 | 6.57 |
| patient 5 | 4.73 | 4.96 |
| patient 6 | NA | 7.42 |
Collected over For up to 6 to 8 cycles, consisting of 28 days each, and for up to a 1-year follow-up period. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VAD Treatment | — | 6/16 (37.5%) | 15/16 (93.8%) |
| PAD Treatment | — | 5/13 (38.5%) | 8/13 (61.5%) |
| Event | VAD Treatment | PAD Treatment |
|---|---|---|
| PneumoniaInfections and infestations | 2/16 | 1/13 |
| Angina unstableCardiac disorders | 0/16 | 1/13 |
| AstheniaGeneral disorders | 0/16 | 1/13 |
| Bursitis infectiveInfections and infestations | 0/16 | 1/13 |
| Cardiac failure chronicCardiac disorders | 0/16 | 1/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/16 | 1/13 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 1/13 |
| NeutropeniaBlood and lymphatic system disorders | 1/16 | 1/13 |
| Pyelonephritis acuteInfections and infestations | 0/16 | 1/13 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/16 | 1/13 |
| Event | VAD Treatment | PAD Treatment |
|---|---|---|
| InsomniaPsychiatric disorders | 2/16 | 4/13 |
| LymphopeniaBlood and lymphatic system disorders | 4/16 | 2/13 |
| NeutropeniaBlood and lymphatic system disorders | 4/16 | 1/13 |
| FatigueGeneral disorders | 3/16 | 2/13 |
| HypertensionVascular disorders | 1/16 | 2/13 |
| Peripheral sensory neuropathyNervous system disorders | 1/16 | 2/13 |
| Back painMusculoskeletal and connective tissue disorders | 2/16 | 1/13 |
| Bronchitis acuteInfections and infestations | 2/16 | 1/13 |
| DiarrhoeaGastrointestinal disorders | 2/16 | 1/13 |
| LeukopeniaBlood and lymphatic system disorders | 2/16 | 0/13 |
| Age, Continuous(years) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| Mean | 64.0 ± 9.4 | 61.5 ± 11.3 | 62.9 ± 10.2 |
| Sex: Female, Male(Participants) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| Female | 5 | 3 | 8 |
| Male | 11 | 10 | 21 |
| Race (NIH/OMB)(Participants) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 16 | 13 | 29 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Karnofsky Performance Status(participants) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| ≤50 | 0 | 0 | 0 |
| 60 | 1 | 1 | 2 |
| 70 | 1 | 3 | 4 |
| 80 | 9 | 3 | 12 |
| 90 | 5 | 3 | 8 |
| 100 | 0 | 3 | 3 |
| Body Surface Area(m2) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| Mean | 1.855 ± 0.233 | 1.924 ± 0.219 | 1.886 ± 0.226 |
| Height(cm) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| Mean | 168.8 ± 11.2 | 169.8 ± 9.5 | 169.3 ± 10.3 |
| Weight(kg) | VAD Treatment | PAD Treatment | Total |
|---|---|---|---|
| Mean | 75.9 ± 15.7 | 78.3 ± 14.5 | 77.0 ± 15.0 |
The record gives a start of Dec 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Janssen-Cilag International NV →